Medincell ROA 2024

Medincell ROA

-1.09

Medincell Dividend yield

Ticker

MEDCL.PA

ISIN

FR0004065605

WKN

A2N6VA

In 2024, Medincell's return on assets (ROA) was -1.09, a 94.86% increase from the -0.56 ROA in the previous year.

Medincell Aktienanalyse

What does Medincell do?

Medincell SA is a leading biotechnology company based in Montpellier, France, specializing in the development and manufacturing of innovative drugs based on its proprietary Intellisome® technology platform. The company was founded in 1999 by Dr. Christophe Douat and has since built an impressive portfolio of products and services. Medincell's business model is based on the development and manufacturing of extended-release drugs through the integration of drugs into the Intellisome® technology platform. This is a novel concept based on the use of polymers that are capable of controlling and slowing down the release of drugs. This allows medications to be administered in a specific dosage and duration, providing greater effectiveness and tolerability for the patient. Medincell has several business areas, including the development of drugs for the treatment of central nervous system (CNS) disorders, including schizophrenia, depression, and chronic pain. The company is also working on the development of drugs for the treatment of infectious diseases and cancer, as well as the development of new technologies for drug manufacturing. Medincell's products include a range of drugs, including Long-Acting Risperidone (a depot preparation for the treatment of schizophrenia), Long-Acting Cabergoline (for the treatment of Parkinson's), and Long-Acting Naltrexone (for the treatment of alcohol and drug addiction). The company also has partnerships with other pharmaceutical companies such as Pierre Fabre, Sanofi, Janssen, and Pfizer for the development of products based on its Intellisome® technology platform. Another important area of Medincell is its service for drug development based on the Intellisome® technology platform. The company offers customers comprehensive support in the development, manufacturing, and approval of extended-release drugs. Customers can choose from a wide range of services, ranging from the identification of active ingredients to the implementation of clinical trials. Overall, Medincell has achieved impressive success in the launch of its products and services based on the Intellisome® technology platform. The company has won several awards for its innovative products and services in the pharmaceutical industry, including the Innovation Award from the European Society of Clinical Microbiology and Infectious Diseases in 2018 and the Excellence in Specialty Pharmaceuticals Award from BioPharm America in 2019. In summary, Medincell SA is a leading company in the biotechnology industry specializing in the development and manufacturing of extended-release drugs based on its Intellisome® technology platform. With an impressive range of products and services and partnerships with several renowned pharmaceutical companies, the company has a promising future as a key player in the pharmaceutical industry. Medincell ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Medincell's Return on Assets (ROA)

Medincell's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Medincell's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Medincell's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Medincell’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Medincell Stock

What is the Return on Assets (ROA) of Medincell this year?

The Return on Assets (ROA) of Medincell is -1.09 undefined this year.

What was the ROA of Medincell compared to the previous year?

The ROA of Medincell has increased by 94.86% compared to the previous year.

What consequences do high ROA have for investors of Medincell?

A high ROA is advantageous for investors of Medincell, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Medincell?

A low ROA can be unfavorable for investors of Medincell as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Medincell affect the company?

An increase in ROA of Medincell can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Medincell impact the company?

A reduction in the ROA of Medincell can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Medincell?

Some factors that can influence the ROA of Medincell include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Medincell important for investors?

The ROA of Medincell is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Medincell take to improve ROA?

To improve ROA, Medincell can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Medincell pay?

Over the past 12 months, Medincell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Medincell is expected to pay a dividend of 0 EUR.

What is the dividend yield of Medincell?

The current dividend yield of Medincell is .

When does Medincell pay dividends?

Medincell pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Medincell?

Medincell paid dividends every year for the past 0 years.

What is the dividend of Medincell?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Medincell located?

Medincell is assigned to the 'Health' sector.

Wann musste ich die Aktien von Medincell kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Medincell from 5/16/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/16/2024.

When did Medincell pay the last dividend?

The last dividend was paid out on 5/16/2024.

What was the dividend of Medincell in the year 2023?

In the year 2023, Medincell distributed 0 EUR as dividends.

In which currency does Medincell pay out the dividend?

The dividends of Medincell are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Medincell stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Medincell

Our stock analysis for Medincell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medincell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.